Alaunos 10-Q: $350M PIPE Erases Going-Concern Doubt, But 381M Conversion Shares Loom
TCRT has more than doubled off its 52-week low of $0.719.
Summary
Alaunos filed its first 10-Q since the Velaris merger and $350 million PIPE, showing going-concern doubt resolved but roughly 381.4 million preferred conversion shares still needing stockholder approval, with cash-settlement rights if that vote fails.
Key Events · Earnings and Guidance · TCRT
-
First Post-Merger Quarterly Report
September 30, 2026 balance sheet shows $0.62 million of cash, a $927.4 million accumulated deficit and a $2.7 million net loss for the nine months; it precedes the October 13 Velaris acquisition and October 14 PIPE.
-
Going-Concern Doubt Cleared
Management concluded the $350.0 million gross PIPE proceeds fund planned operations for at least one year from the issuance date, alleviating the substantial doubt previously raised.
-
381.4M Conversion Shares Need Approval
Series B and Series C preferred convert into roughly 381.4 million common shares against 4.2 million outstanding as of November 16; without stockholder approval, holders can demand cash settlement beginning six months after issuance, and only 6,268 Series C shares (~$9.0 million) are waived.
-
Paragon $200M Equity Trigger
Paragon may terminate the licenses, with rights reverting, if stockholders' equity does not exceed $200 million at the end of the second full fiscal quarter after the October 13 closing.
Analysis · TCRT · Life Sciences
This is the first full look at Alaunos after the Velaris asset acquisition and the $350.0 million PIPE closed in mid-October. The September 30 balance sheet still shows the old shell: $0.62 million of cash, a $927.4 million accumulated deficit and a $2.7 million nine-month net loss. Management now says the PIPE proceeds fund operations for at least a year, so the going-concern warning is gone. The catch is the structure: the Series B and Series C preferred convert into roughly 381.4 million common shares, against 4.2 million shares outstanding as of November 16, and if stockholders do not approve the conversion, holders can demand cash settlement beginning six months after issuance. Only 6,268 Series C shares, about $9.0 million, are covered by Fairmount's waiver, so a failed vote could force a cash payment that exceeds the company's resources. The proxy vote on that conversion is the event that decides whether this is a funded biotech or a cash-settlement problem.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.72 to $4.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.